| Stromal disrupting effects of nab-paclitaxel in pancreatic cancer R Alvarez, M Musteanu, E Garcia-Garcia, PP Lopez-Casas, D Megias, ... British journal of cancer 109 (4), 926-933, 2013 | 303 | 2013 |
| Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment E Garralda, K Paz, PP López-Casas, S Jones, A Katz, LM Kann, ... Clinical Cancer Research 20 (9), 2476-2484, 2014 | 179 | 2014 |
| SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III … M Hidalgo, C Plaza, M Musteanu, P Illei, CB Brachmann, C Heise, ... Clinical Cancer Research 21 (21), 4811-4818, 2015 | 141 | 2015 |
| CDK4/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma B Salvador-Barbero, M Álvarez-Fernández, E Zapatero-Solana, ... Cancer Cell 37 (3), 340-353. e6, 2020 | 139 | 2020 |
| Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in … LD Engstrom, R Aranda, M Lee, EA Tovar, CJ Essenburg, Z Madaj, ... Clinical Cancer Research 23 (21), 6661-6672, 2017 | 124 | 2017 |
| Afatinib restrains K-RAS–driven lung tumorigenesis HP Moll, K Pranz, M Musteanu, B Grabner, N Hruschka, J Mohrherr, ... Science translational medicine 10 (446), eaao2301, 2018 | 120 | 2018 |
| c-Raf ablation induces regression of advanced KRas/Trp53 mutant lung adenocarcinomas by a mechanism independent of MAPK signaling M Sanclemente, S Francoz, L Esteban-Burgos, E Bousquet-Mur, M Djurec, ... Cancer cell 33 (2), 217-228. e4, 2018 | 115 | 2018 |
| Immunotherapeutic effects of intratumoral nanoplexed poly I: C MA Aznar, L Planelles, M Perez-Olivares, C Molina, S Garasa, I Etxeberría, ... Journal for immunotherapy of cancer 7, 1-16, 2019 | 110 | 2019 |
| Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft MP Morelli, E Calvo, E Ordoñez, MJ Wick, BR Viqueira, PP Lopez-Casas, ... Journal of Clinical Oncology 30 (4), e45, 2012 | 94 | 2012 |
| Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma A Kalbasi, M Tariveranmoshabad, K Hakimi, S Kremer, KM Campbell, ... Science translational medicine 12 (565), eabb0152, 2020 | 89 | 2020 |
| Genetic aberrations in DNA repair pathways: A cornerstone of precision oncology in prostate cancer R Lozano, E Castro, IM Aragón, Y Cendón, C Cattrini, PP López-Casas, ... British journal of cancer 124 (3), 552-563, 2021 | 84 | 2021 |
| The expression patterns of genes involved in the RNAi pathways are tissue-dependent and differ in the germ and somatic cells of mouse testis E González-González, PP López-Casas, J del Mazo Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1779 (5), 306-311, 2008 | 78 | 2008 |
| PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data E Piñeiro-Yáñez, M Reboiro-Jato, G Gómez-López, J Perales-Patón, ... Genome medicine 10, 1-11, 2018 | 72 | 2018 |
| Intratumoral nanoplexed poly I: C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors I Márquez-Rodas, F Longo, ME Rodriguez-Ruiz, A Calles, S Ponce, ... Science Translational Medicine 12 (565), eabb0391, 2020 | 64 | 2020 |
| Personalized RNA medicine for pancreatic cancer ME Gilles, L Hao, L Huang, R Rupaimoole, PP Lopez-Casas, E Pulver, ... Clinical Cancer Research 24 (7), 1734-1747, 2018 | 63 | 2018 |
| Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab RA Toledo, A Cubillo, E Vega, E Garralda, R Alvarez, LU de la Varga, ... Oncotarget 8 (21), 35289, 2017 | 60 | 2017 |
| SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic cancer xenografts H Kim, S Samuel, P Lopez-Casas, W Grizzle, M Hidalgo, J Kovar, ... Molecular cancer therapeutics 15 (4), 680-688, 2016 | 57 | 2016 |
| The effects of different endocrine disruptors defining compound-specific alterations of gene expression profiles in the developing testis PP López-Casas, SC Mizrak, LA López-Fernández, M Paz, DG de Rooij, ... Reproductive toxicology 33 (1), 106-115, 2012 | 56 | 2012 |
| OMTX705, a novel FAP-Targeting ADC demonstrates activity in chemotherapy and Pembrolizumab-Resistant solid tumor models M Fabre, C Ferrer, S Domínguez-Hormaetxe, B Bockorny, L Murias, ... Clinical Cancer Research 26 (13), 3420-3430, 2020 | 53 | 2020 |
| Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer R Lozano, DC Salles, S Sandhu, IM Aragón, H Thorne, F López-Campos, ... European Journal of Cancer 147, 74-83, 2021 | 46 | 2021 |
Manuel HidalgoWeill Cornell MedicineAdresse e-mail validée de med.cornell.edu
